Evidence map›Paper›PMID 39095369›Full record

ArticleScientific reports2024

Fabrication of novel vildagliptin loaded ZnO nanoparticles for anti diabetic activity.

Abdul Samad, Sammia Shahid, Sana Mansoor, Sehrish Afzal, Mohsin Javed, Ammar Zidan, Abdullah Shoaib, Fadi Jaber, Shahid Iqbal, Muhammad Saad and 3 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors.

Abdul SamadDepartment of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
Sammia ShahidDepartment of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
Sana MansoorDepartment of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
Sehrish AfzalDepartment of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
Mohsin JavedDepartment of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
Ammar ZidanBiomedical Engineering Department, College of Engineering and Technologies, Al-Mustaqbal University, Babylon, 51001, Iraq.
Abdullah ShoaibDepartment of Chemistry, School of Science, University of Management and Technology, Lahore, 54770, Pakistan.
Fadi JaberDepartment of Biomedical Engineering, Ajman University, Ajman, UAE. f.jaber@ajman.ac.ae.
Shahid IqbalNottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo, 315100, China. shahidiqbal@hzu.edu.cn.
Muhammad SaadCentre for Organic and Nanohybrid Electronics, Silesian University of Technology, Konarskiego 22B, 44-100, Gliwice, Poland. saad.miana786@gmail.com.
Sajid MahmoodNottingham Ningbo China Beacons of Excellence Research and Innovation Institute, University of Nottingham Ningbo China, Ningbo, 315100, China. sajidmahmood1987@yahoo.com.
Nasser S AwwadChemistry Department, Faculty of Science, King Khalid University, PO Box 9004, 61413, Abha, Saudi Arabia.
Hala A IbrahiumBiology Department, Faculty of Science, King Khalid University, PO Box 9004, 61413, Abha, Saudi Arabia.

Funding

King Khalid University RGP2/144/45
6 · The paper itself

Abstract

Diabetes mellitus (DM) is a rapidly prevailing disease throughout the world that poses boundless risk factors linked to several health problems. Vildagliptin is the standard dipeptidyl peptidase-4 (DPP-4) inhibitor type of medication that is used for the treatment of diabetes anti-hyperglycemic agent (anti-diabetic drug). The current study aimed to synthesize vildagliptin-loaded ZnO NPs for enhanced efficacy in terms of increased retention time minimizing side effects and increased hypoglycemic effects. Herein, Zinc Oxide (ZnO) nanoparticles (NPs) were constructed by precipitation method then the drug vildagliptin was loaded and drug loading efficiency was estimated by the HPLC method. X-ray diffraction analysis (XRD), UV-vis spectroscopy, FT-IR, scanning electron microscope (SEM), and EDX analysis were performed for the characterization of synthesized vildagliptin-loaded ZnO NPs. The UV-visible spectrum shows a distinct peak at 363 nm which confirms the creation of ZnO NPs and SEM showed mono-dispersed sphere-shaped NPs. EDX analysis shows the presence of desired elements along with the elemental composition. The physio-sorption studies, which used adsorption isotherms to assess adsorption capabilities, found that the Freundlich isotherm model explains the data very well and fits best. The maximum adsorption efficiency of 58.83% was obtained. Further, In vitro, anti-diabetic activity was evaluated by determining the α-amylase and DPP IV inhibition activity of the product formed. The formulation gave maximum inhibition of 82.06% and 94.73% of α-amylase and DPP IV respectively. While at 1000 µg/ml concentration with IC

Indexed as

Hypoglycemic AgentsNanoparticlesVildagliptinZinc OxideDipeptidyl-Peptidase IV InhibitorsDrug CarriersHumansNitrilesSpectroscopy, Fourier Transform InfraredX-Ray DiffractionDipeptidyl-Peptidase IV InhibitorsDrug CarriersHypoglycemic AgentsNitrilesVildagliptinZinc OxideDiabetesDipeptidyl peptidase-4 (DPP-4) inhibitorMetal oxide NPsVildagliptin

Identifiers

PMID39095369
PMCPMC11297240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.